| Literature DB >> 29067670 |
Benjamin Duchêne1, Jean-Paul Iyombe-Engembe1, Joël Rousseau1, Jacques P Tremblay1, Dominique L Ouellet2.
Abstract
The discovery of the CRISPR-Cas9 system raises hope for the treatment of many genetic disorders. We describe here an approach based on the use of a pair of single guide RNAs to form a hybrid exon that does not only restore the dystrophin gene reading frame but also results in the production of a dystrophin protein with an adequate structure of the central rod-domain, with a correct spectrin-like repeat. The therapeutic approach described here involved DMD patient cells having a deletion of exons 51-53 of the DMD gene.Entities:
Keywords: CRISPR-Cas9; Duchenne muscular dystrophy (DMD); Dystrophin; Hybrid exon; Spectrin-like repeats
Mesh:
Substances:
Year: 2018 PMID: 29067670 DOI: 10.1007/978-1-4939-7374-3_19
Source DB: PubMed Journal: Methods Mol Biol ISSN: 1064-3745